IL6 and cancer: In terms of a potential cancer therapy, inhibition of the strongly pro‐inflammatory SASP is likely to be a considerable advantage, since pro‐inflammatory signalling, through IL‐6 in particular, has been linked to tumour progression and metastasis (He et al., 2013; Kim et al., 2009).